Can Hexasim (hexavalent vaccine) and Infanrix (diphtheria, tetanus, and pertussis vaccine) be used interchangeably?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Interchangeability of Hexaxim and Infanrix Vaccines

Hexaxim (hexavalent vaccine) and Infanrix (DTaP vaccine) cannot be used interchangeably as they contain different antigens and are designed for different vaccination purposes. 1

Vaccine Composition and Indications

Infanrix (DTaP)

  • Infanrix is a DTaP (diphtheria, tetanus, acellular pertussis) vaccine licensed for active vaccination against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years 1
  • Contains diphtheria and tetanus toxoids plus three pertussis antigens (pertussis toxin, filamentous hemagglutinin, and pertactin) 1
  • Designed to be part of the routine childhood immunization schedule as a standalone DTaP vaccine or in combination products 1

Hexaxim (Hexavalent)

  • Hexaxim is a fully liquid, hexavalent combination vaccine that provides immunization against six diseases: diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b 2, 3
  • Approved for primary and booster vaccination in infants 6 weeks and older 2
  • Contains additional antigens beyond those in Infanrix, making it a more comprehensive but different vaccine product 3

Guidelines on Vaccine Interchangeability

General Principles

  • The Advisory Committee on Immunization Practices (ACIP) recommends that whenever feasible, the same brand of DTaP vaccine should be used for all doses of the vaccination series 1
  • However, if the vaccine provider does not know or does not have available the type of DTaP vaccine previously administered, this should not present a barrier to vaccination 1
  • In such cases, any of the licensed DTaP vaccines may be used to complete the vaccination series 1

Specific Guidance

  • There are limited data regarding the safety, immunogenicity, and efficacy of using DTaP vaccines from different manufacturers for successive doses 1
  • The ACIP states: "Data do not exist regarding the safety, immunogenicity, and efficacy of using DTaP vaccines from different manufacturers for successive doses of the primary or booster vaccination series" 1
  • For hexavalent vaccines specifically, studies show Hexaxim can be given as a booster for infants primed with Infanrix Hexa (a different hexavalent vaccine), but not with Infanrix DTaP alone 2

Clinical Considerations

Safety and Efficacy

  • Both vaccines have demonstrated good safety profiles in their respective clinical trials 2, 4
  • Switching between different vaccine products or manufacturers may have unknown effects on overall immunity and protection 1
  • Hexaxim has been shown to be non-inferior to other licensed hexavalent vaccines in terms of immunogenicity 2

Practical Implications

  • Using the correct vaccine for the intended purpose is crucial for ensuring proper immunization coverage 1
  • Infanrix (DTaP) does not provide protection against hepatitis B, polio, or Haemophilus influenzae type b, which are covered by Hexaxim 1, 2
  • Combination vaccines like Hexaxim reduce the number of injections needed, potentially improving vaccination compliance 3

Common Pitfalls to Avoid

  • Do not substitute a hexavalent vaccine (Hexaxim) for a trivalent vaccine (Infanrix) as this would result in missing protection against three diseases 2, 4
  • Do not assume that all DTaP-containing vaccines are interchangeable without reviewing their specific components 1
  • When switching between vaccine brands is unavoidable, ensure that all required antigens for the child's age and vaccination schedule are provided 1
  • Always verify the specific licensed indications for each vaccine product, as they may vary in terms of approved age ranges and dosing schedules 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.